Harvard Bioscience’s (HBIO) “Sector Weight” Rating Reaffirmed at KeyCorp

Harvard Bioscience (NASDAQ:HBIO)‘s stock had its “sector weight” rating reaffirmed by stock analysts at KeyCorp in a report issued on Wednesday, Marketbeat reports.

Separately, Benchmark reduced their target price on Harvard Bioscience from $5.50 to $4.50 and set a “speculative buy” rating on the stock in a report on Monday, March 24th.

Harvard Bioscience Trading Down 16.0 %

Shares of HBIO opened at $0.39 on Wednesday. Harvard Bioscience has a 1-year low of $0.36 and a 1-year high of $4.45. The company has a current ratio of 2.06, a quick ratio of 0.91 and a debt-to-equity ratio of 0.52. The firm’s 50-day moving average price is $0.85 and its 200-day moving average price is $1.74. The firm has a market capitalization of $17.00 million, a price-to-earnings ratio of -1.17 and a beta of 1.47.

Institutional Trading of Harvard Bioscience

A number of hedge funds have recently modified their holdings of HBIO. Focus Partners Wealth bought a new position in shares of Harvard Bioscience in the 4th quarter worth about $28,000. Intech Investment Management LLC purchased a new stake in Harvard Bioscience in the fourth quarter worth about $35,000. Sei Investments Co. bought a new position in shares of Harvard Bioscience during the fourth quarter valued at approximately $47,000. Jane Street Group LLC lifted its holdings in shares of Harvard Bioscience by 55.5% during the fourth quarter. Jane Street Group LLC now owns 35,769 shares of the medical instruments supplier’s stock valued at $75,000 after purchasing an additional 12,767 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its holdings in shares of Harvard Bioscience by 63.0% during the third quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock valued at $79,000 after purchasing an additional 11,397 shares during the last quarter. Institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.